Phase 3 Depression and Anxiety Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with recurrent moderate or severe major depressive disorder (MDD), or with persistent depressive disorder (long-lasting depression)
- People whose depression has not improved enough with antidepressant tablets or capsules taken by mouth during their current episode of depression
- People who have been taking oral antidepressants for at least 8 weeks and are willing to continue taking the same medication at the same dose throughout the study
- People whose depression symptoms score at or above a certain level of severity (a score of 22 or higher on a standard depression rating scale) at both the screening visit and the first day of the study
- People who, in the opinion of the study doctor, are willing and able to follow all study procedures and requirements
Who may not be able to join:
- People who have been diagnosed with another mental health condition in the past year that was the main focus of their treatment, other than MDD
- People whom the study doctor considers to be at immediate risk of suicide or of harming themselves or others
- People whose depression symptoms have previously not responded to electroconvulsive therapy (ECT) during their current depressive episode
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Development Lead, Neurocrine Biosciences
Phone: 1-877-641-3461
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change from Baseline in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Day 56
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.